

TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CA

Lancet, The

316, 390-392

DOI: 10.1016/s0140-6736(80)90440-7

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting toxins – the reticular approach to chemotherapy. Trends in Biochemical Sciences, 1981, 6, 313-316.	7.5	10
2	Radioimmunochemical measurement of the transferrin receptor in human trophoblast and reticulocyte membranes with a specific anti-receptor antibody.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 4222-4225.	7.1	72
3	Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells. Nature, 1981, 294, 171-173.	27.8	269
4	Iron and neoplasia. Biological Trace Element Research, 1981, 3, 55-80.	3.5	42
5	Iron in neoplastic disease. Nutrition and Cancer, 1982, 4, 223-233.	2.0	39
6	Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 1175-1179.	7.1	315
7	Transferrin receptors of human fibroblasts. Analysis of receptor properties and regulation. Biochemical Journal, 1982, 208, 19-26.	3.7	75
8	Human amniochorion: Tissue-specific markers, transferrin receptors and histocompatibility antigens. Placenta, 1982, 3, 1-11.	1.5	54
9	Transferrin receptor affinity and iron transport in the human placenta. Placenta, 1982, 3, 21-27.	1.5	32
10	Loss of transferrin receptors following induced differentiation of HL-60 promyelocytic leukemia cells. Experimental Cell Research, 1982, 138, 429-433.	2.6	58
11	Hemin regulates the expression of transferrin receptors in human hematopoietic cell lines. FEBS Letters, 1982, 145, 350-354.	2.8	50
12	Biological meaning of stage and grade in human breast cancer: Review and hypothesis. Breast Cancer Research and Treatment, 1982, 2, 299-322.	2.5	14
13	Murine cell surface transferrin receptor: Studies with an anti-receptor monoclonal antibody. Journal of Cellular Physiology, 1982, 112, 403-410.	4.1	128
14	Selection and properties of a mouse L-cell transformant expressing human transferrin receptor. Nature, 1983, 304, 643-645.	27.8	53
15	Uptake and release of transferrin and iron by mitogen-stimulated human lymphocytes. British Journal of Haematology, 1983, 55, 93-101.	2.5	44
16	Distribution of the transferrin receptor in normal human fibroblasts and fibrosarcoma cells. International Journal of Cancer, 1983, 31, 111-117.	5.1	49
17	Histocompatibility antigens, transferrin receptors and extra-embryonic markers of human amniotic epithelial cells in vitro. Placenta, 1983, 4, 361-368.	1.5	15
18	CORRELATION OF TRANSFERRIN RECEPTOR EXPRESSION WITH HISTOLOGICAL CLASS AND OUTCOME IN NON-HODGKIN LYMPHOMA. Lancet, The, 1983, 321, 498-501.	13.7	172

#	ARTICLE	IF	CITATIONS
19	Transferrin receptors in human tissues: their distribution and possible clinical relevance.. Journal of Clinical Pathology, 1983, 36, 539-545.	2.0	483
20	Evidence for polymorphism of transferrin receptors in human skin.. Journal of Clinical Pathology, 1983, 36, 1414-1415.	2.0	4
21	Demonstration of an epitope of the transferrin receptor in human cervical epithelium—a potentially useful cell marker.. Journal of Clinical Pathology, 1984, 37, 131-135.	2.0	47
22	Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue.. Journal of Clinical Pathology, 1984, 37, 51-55.	2.0	66
23	Isolation and characterization of transferrin receptor from embryonic chicken red cell. The Protein Journal, 1984, 3, 19-33.	1.1	6
24	Transferrin Binding by Peripheral Blood Mononuclear Cells in Human Lymphomas, Myelomas and Leukemias. Vox Sanguinis, 1984, 46, 217-223.	1.5	35
25	Increase of transferrin receptors in hepatocytes during rat liver regeneration. International Journal of Biochemistry & Cell Biology, 1984, 16, 601-605.	0.5	13
26	Transferrin receptor and B-lymphoblast antigen " their relationship to DNA synthesis, histology and survival in B-cell lymphomas. International Journal of Cancer, 1984, 33, 173-177.	5.1	55
27	Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clinical Immunology and Immunopathology, 1984, 32, 1-11.	2.0	42
28	Effect of an anti-murine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro. Experimental Cell Research, 1984, 150, 400-407.	2.6	38
29	Selection of cell lines resistant to anti-transferrin receptor antibody: evidence for a mutation in transferrin receptor.. Molecular and Cellular Biology, 1984, 4, 1675-1681.	2.3	28
30	Identification and characterization of the chicken transferrin receptor. Biochemical Journal, 1985, 232, 735-741.	3.7	27
31	Transferrin receptors in cultured breast cancer cells. Journal of Cancer Research and Clinical Oncology, 1985, 110, 71-76.	2.5	21
32	Distribution and mechanism of uptake of ¹¹¹ InCl ₃ in a tumor model for lymph node metastases. International Journal of Nuclear Medicine and Biology, 1985, 12, 89-96.	0.3	3
33	Interaction of oxidized chicken ovotransferrin with chicken embryo red blood cells. BBA - Proteins and Proteomics, 1985, 827, 389-395.	2.1	1
34	Tumor-associated antigens—an overview.. Journal of Clinical Oncology, 1985, 3, 876-882.	1.6	10
35	Antitrypsin, Transferrin, Alkaline Phosphatase, Phosphohexoseisomerase and ³ -Glutamyltransferase in Breast Cyst Fluid. Tumori, 1985, 71, 135-140.	1.1	12
36	A rapid and efficient microtechnique for the analysis of functional transferrin receptors on tumor cells. Journal of Immunological Methods, 1985, 79, 213-221.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Influence of iron on infection. American Journal of Surgery, 1986, 151, 291-295.	1.8	22
38	Extramammary Paget's cells: Further evidence of sweat gland derivation. Journal of the American Academy of Dermatology, 1986, 15, 1275-1281.	1.2	40
39	The Immunoregulatory Nature of Iron. II. Lymphocyte Surface Marker Expression. Journal of Leukocyte Biology, 1986, 40, 589-600.	3.3	18
40	Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6627-6630.	7.1	57
41	Determination of transferrin receptors on frozen sections of malignant B-cell lymphomas by immunofluorescence with a monoclonal antibody. Cancer, 1986, 58, 1252-1259.	4.1	18
42	Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. Virchows Archiv A, Pathological Anatomy and Histopathology, 1986, 410, 69-73.	1.4	38
43	Continuous growth of human tumor cell lines in serum-free media. In Vitro Cellular & Developmental Biology, 1986, 22, 369-374.	1.0	12
44	Transferrin receptor is inversely correlated with estrogen receptor in breast cancer. Breast Cancer Research and Treatment, 1986, 7, 71-76.	2.5	33
45	Normal epithelial antigens recognized by GB3 and GB5 are diminished in intraductal and lost in infiltrating human breast carcinomas. Breast Cancer Research and Treatment, 1986, 8, 117-123.	2.5	5
46	Transferrin Receptor Expression and the Control of Cell Growth. Cancer Investigation, 1986, 4, 461-470.	1.3	55
47	Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Journal of Neurosurgery, 1987, 66, 850-861.	1.6	73
48	[23] Radioimmunoassay of transferrin receptor. Methods in Enzymology, 1987, 147, 253-265.	1.0	1
49	Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours <i>in vivo</i> . Immunology and Cell Biology, 1987, 65, 461-472.	2.3	36
50	Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). British Journal of Haematology, 1988, 68, 379-384.	2.5	29
51	Transferrin receptor expression on AML blasts is related to their proliferative potential. British Journal of Haematology, 1988, 69, 275-280.	2.5	17
52	Transferrin receptor expression by non-hodgkin's lymphomas. Correlation with morphologic grade and survival. Cancer, 1988, 61, 1844-1851.	4.1	31
53	Sensitivity of human glioma cells to cytotoxic heteroconjugates. International Journal of Cancer, 1988, 42, 441-448.	5.1	36
54	Modulation of the transferrin receptor during DMSO-induced differentiation in HL-60 cells. Experimental Cell Research, 1988, 174, 89-97.	2.6	21

#	ARTICLE	IF	CITATIONS
55	Expression of Transferrin Receptor in Normal Human Skin, Psoriatic Skin and Various Skin Tumors. <i>Journal of Dermatology</i> , 1988, 15, 208-211.	1.2	4
56	Regulation of the hepatic transferrin receptor in hereditary hemochromatosis. <i>Hepatology</i> , 1989, 9, 1-5.	7.3	59
57	Transferrin receptor and ferritin levels during murine mammary gland development. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1989, 1010, 1-6.	4.1	19
58	Recent Advances in Cancer Research: Drug Targeting Without the Use of Monoclonal Antibodies. <i>American Journal of Reproductive Immunology</i> , 1989, 21, 151-154.	1.2	17
60	Characteristics of a breast cancer-associated antigen defined by RCC-1 antibody. <i>Immunology and Cell Biology</i> , 1990, 68, 191-198.	2.3	0
61	Transferrin receptors in injured brain. <i>Acta Neuropathologica</i> , 1990, 79, 686-688.	7.7	25
62	Epidermal growth factor receptors on ependymomas and other brain tumors. <i>Journal of Neurosurgery</i> , 1990, 72, 641-646.	1.6	39
63	Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 4033-4037.	7.1	337
64	Transferrin Receptor Expression in Adenocarcinoma of the Lung as a Histopathologic Indicator of Prognosis. <i>Chest</i> , 1990, 97, 1367-1371.	0.8	62
65	Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. <i>Journal of Neurosurgery</i> , 1990, 72, 941-945.	1.6	165
66	Tissue distribution of 131I radiolabeled transferrin in the athymic nude mouse: Localization of a human colon adenocarcinoma HT-29 xenograft. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1990, 17, 209-216.	0.3	4
67	Cellular Iron Metabolism in Health and Diseased. <i>Drug Metabolism Reviews</i> , 1990, 22, 531-579.	3.6	112
68	Ferritin and transferrin levels in human breast cyst fluids: relationship with intracystic electrolyte concentrations. <i>Clinica Chimica Acta</i> , 1990, 192, 1-7.	1.1	8
69	Diferic transferrin reduction by K562 cells. A critical study. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1991, 1073, 562-570.	2.4	21
70	Localization of estrogen, epidermal growth factor, and transferrin receptors in human prostatic carcinoma.. <i>Acta Histochemica Et Cytochemica</i> , 1991, 24, 61-67.	1.6	4
71	Immunotherapy for Recurrent Spontaneous Abortion and its Analogies to Treatment for Cancer. <i>American Journal of Reproductive Immunology</i> , 1991, 25, 114-119.	1.2	14
72	Transferrin Receptor Activity as a Marker in Transitional Cell Carcinoma of the Bladder. <i>British Journal of Urology</i> , 1991, 67, 165-168.	0.1	23
73	Evidence in Support of the Plasma Membrane as the Target for Transferrin-Adriamycin Conjugates in K562 Cells. <i>American Journal of Reproductive Immunology</i> , 1991, 25, 120-123.	1.2	16

#	ARTICLE	IF	CITATIONS
74	Characterization of the Anti-Cancer Activity of Transferrin-Adriamycin Conjugates. American Journal of Reproductive Immunology, 1992, 27, 163-166.	1.2	11
75	In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. Journal of Neurosurgery, 1992, 76, 838-844.	1.6	50
76	Selective stimulation of prostatic carcinoma cell proliferation by transferrin.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6197-6201.	7.1	75
77	Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1105, 84-88.	2.6	33
78	Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase? in human tumour lines: implications for in vitro chemoresistance. Journal of Cancer Research and Clinical Oncology, 1992, 118, 116-122.	2.5	9
79	Roles of iron in neoplasia. Biological Trace Element Research, 1992, 34, 123-140.	3.5	47
80	(C) Means to enhance penetration. Advanced Drug Delivery Reviews, 1992, 8, 93-113.	13.7	51
81	Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. International Journal of Cancer, 1992, 52, 619-623.	5.1	37
82	Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. Journal of Cellular Physiology, 1993, 156, 212-217.	4.1	103
83	Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemotherapy and Pharmacology, 1993, 31, 357-362.	2.3	27
84	Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. FEBS Journal, 1993, 213, 427-436.	0.2	27
85	Breast Carcinoma and the Role of Iron Metabolism.. Annals of the New York Academy of Sciences, 1993, 698, 159-166.	3.8	88
86	Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. Journal of Neurosurgery, 1994, 80, 520-526.	1.6	101
87	Electron microscopic and immunohistochemical studies of oral malignant melanoma. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 1994, 27, 41-44.	1.8	2
88	Response to adriamycin of transplasma membrane electron transport in adriamycin-resistant and nonresistant HL-60 cells. Journal of Bioenergetics and Biomembranes, 1994, 26, 137-142.	2.3	7
89	High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: A preventive mechanism of malignant tumor cells against complement attack?. Breast Cancer Research and Treatment, 1994, 32, 213-219.	2.5	32
90	Relationship of serum and tumor levels of iron and iron-binding proteins to lymphocyte immunity against tumor antigen in breast cancer patients. Breast Cancer Research and Treatment, 1994, 30, 305-309.	2.5	8
91	Effect of reductive alkylation on transferrin conformation and physicochemical properties. Analytica Chimica Acta, 1994, 290, 65-74.	5.4	7

#	ARTICLE	IF	CITATIONS
92	Transferrin receptor in oral tumors. International Journal of Oral and Maxillofacial Surgery, 1994, 23, 430-433.	1.5	36
93	The expression of ferritin on renal cancers and its relationship with cellular differentiation and tumour stage. British Journal of Urology, 1995, 75, 733-735.	0.1	4
94	A chimeric saporinâ€transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. FASEB Journal, 1995, 9, 1220-1225.	0.5	36
95	A review of new oncotropic tracers for pet imaging. Nuclear Medicine and Biology, 1996, 23, 669-672.	0.6	4
96	Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochemical Pharmacology, 1996, 51, 489-493.	4.4	40
97	The transferrin receptor. Biomembranes: A Multi-Volume Treatise, 1996, 4, 255-287.	0.1	6
98	Expression of Insulin-Like Growth Factor-I Receptor and Transferrin Receptor By Breast Cancer Cells In Pleural Effusion Smears. Cytopathology, 1996, 7, 400-405.	0.7	3
99	Soluble and cell-associated transferrin receptor in lung cancer. British Journal of Cancer, 1997, 75, 1802-1806.	6.4	33
100	Nitric Oxide Prevents Oxidative Damage Produced by tert-Butyl Hydroperoxide in Erythroleukemia Cells via Nitrosylation of Heme and Non-heme Iron. Journal of Biological Chemistry, 1997, 272, 12328-12341.	3.4	70
101	A Phase II Trial of Deferoxamine in Patients with Hormone-Refractory Metastatic Prostate Cancer. Cancer Investigation, 1997, 15, 311-317.	1.3	18
102	Intraventricular Immunotoxin Therapy for Leptomeningeal Neoplasia. Neurosurgery, 1997, 41, 1039-1051.	1.1	88
103	Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Medicine, 1997, 3, 1362-1368.	30.7	517
104	Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?. Journal of Bioenergetics and Biomembranes, 1997, 29, 269-280.	2.3	38
105	Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in Vivo by using transferrin receptor pathways. Magnetic Resonance in Medicine, 1998, 40, 236-242.	3.0	159
106	Liposomal delivery of Î±-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis. Drug Delivery, 1998, 5, 111-118.	5.7	7
107	Transferrin Trojan Horses as a Rational Approach for the Biological Delivery of Therapeutic Peptide Domains. Journal of Biological Chemistry, 1999, 274, 24066-24073.	3.4	20
108	Iron Chelators Inhibit the Growth and Induce the Apoptosis of Kaposi's Sarcoma Cells and of their Putative Endothelial Precursors. Journal of Investigative Dermatology, 2000, 115, 893-900.	0.7	83
109	In vivo gene delivery to tumor cells by transferrinâ€streptavidinâ€DNA conjugate. FASEB Journal, 2000, 14, 2108-2018.	0.5	48

#	ARTICLE	IF	CITATIONS
110	Preparation, biodistribution, and micropet imaging of ⁴⁵ Ti- ϵ -transferrin. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S793.	1.0	3
111	p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. <i>Carcinogenesis</i> , 2001, 22, 1607-1614.	2.8	75
112	An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10706-10711.	7.1	71
113	Synthesis of 1,3,5-cis,cis-Triaminocyclohexane N-Pyridyl Derivatives as Potential Antitumor Agents. <i>Journal of Organic Chemistry</i> , 2002, 67, 8072-8078.	3.2	16
114	Copper and iron complexes with antitumour activity. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 789-818.	5.0	11
115	Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. <i>Cancer Letters</i> , 2002, 179, 151-156.	7.2	91
116	Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. <i>International Journal of Cancer</i> , 2002, 99, 130-137.	5.1	213
117	Complexation of ytterbium to human transferrin and its uptake by K562 cells. <i>FEBS Journal</i> , 2002, 269, 6082-6090.	0.2	28
118	Synthesis of Chlorin e6-Transferrin and Demonstration of Its Light-Dependent in vitro Breast Cancer Cell Killing Ability. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 117-130.	2.5	34
119	Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2003, 65, 3-14.	2.9	274
120	Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2003, 55, 1439-1466.	13.7	160
121	^{99m} Tc-labelled human serum transferrin for tumour imaging: an in vitro and in vivo study of the complex. <i>Nuclear Medicine Communications</i> , 2004, 25, 387-391.	1.1	10
122	A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. <i>Blood</i> , 2004, 103, 1838-1845.	1.4	101
123	Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. <i>Blood</i> , 2005, 106, 3191-3199.	1.4	72
124	Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5961-5967.	3.0	10
125	Murine monoclonal antibodies in breast cancer: An overview. <i>British Journal of Surgery</i> , 2005, 75, 1067-1077.	0.3	18
126	Heme, heme oxygenase and ferritin in vascular endothelial cell injury. <i>Molecular Nutrition and Food Research</i> , 2005, 49, 1030-1043.	3.3	111
127	Infusion rates and drug distribution in brain tumor models in rats. <i>Journal of Neurosurgery: Pediatrics</i> , 2005, 102, 53-58.	1.3	13

#	ARTICLE	IF	CITATIONS
128	Investigation of Genetic Variants of Genes of the Hemochromatosis Pathway and Their Role in Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1102-1107.	2.5	35
129	Autoantibodies unmasked by redox reactions. <i>Journal of Autoimmunity</i> , 2005, 24, 311-317.	6.5	61
130	Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 60, 295-303.	4.3	97
131	Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells. <i>British Journal of Cancer</i> , 2006, 95, 189-196.	6.4	49
132	Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. <i>Cancer Letters</i> , 2006, 238, 188-196.	7.2	95
133	Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. <i>Blood</i> , 2006, 108, 2745-2754.	1.4	50
134	The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. <i>Clinical Immunology</i> , 2006, 121, 144-158.	3.2	525
135	The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. <i>Antiviral Research</i> , 2006, 69, 60-69.	4.1	134
136	Effects of Transferrin Receptor Blockade on Cancer Cell Proliferation and Hypoxia-Inducible Factor Function and Their Differential Regulation by Ascorbate. <i>Cancer Research</i> , 2006, 66, 2749-2756.	0.9	66
137	Iron chelators as therapeutic iron depletion agents. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1533-1556.	5.0	32
138	Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery. <i>Drug Target Insights</i> , 2007, 2, 117739280700200.	1.4	49
139	Heme, Heme Oxygenase, and Ferritin: How the Vascular Endothelium Survives (and Dies) in an Iron-Rich Environment. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 2119-2138.	5.4	174
140	Does excess iron play a role in breast carcinogenesis? an unresolved hypothesis. <i>Cancer Causes and Control</i> , 2007, 18, 1047-1053.	1.8	108
141	Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. <i>Leukemia</i> , 2008, 22, 42-48.	7.2	53
142	Synthesis and Evaluation of Novel Polyaminocarboxylate-Based Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2208-2215.	6.4	24
143	Lactoferrin and Cancer Disease Prevention. <i>Critical Reviews in Food Science and Nutrition</i> , 2008, 49, 203-217.	10.3	75
144	The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase III α in Breast Cancer Cells. <i>Cancer Research</i> , 2009, 69, 948-957.	0.9	130
145	Discriminant analysis of trace elements in normal, benign and malignant breast tissues measured by total reflection X-ray fluorescence. <i>Spectrochimica Acta, Part B: Atomic Spectroscopy</i> , 2009, 64, 587-592.	2.9	33

#	ARTICLE	IF	CITATIONS
146	Ferritin for the clinician. <i>Blood Reviews</i> , 2009, 23, 95-104.	5.7	433
147	Bile acid-based polyaminocarboxylate conjugates as targeted antitumor agents. <i>Chemical Communications</i> , 2009, , 3011.	4.1	25
148	Status of Transferrin Receptors in Benign and Malignant Lesions of the Cervix. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1987, 13, 481-484.	0.0	1
149	Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. <i>Medical Oncology</i> , 2010, 27, 268-277.	2.5	92
150	Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. <i>BMC Cancer</i> , 2010, 10, 72.	2.6	13
151	Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7 β -APTADD to breast cancer cells. <i>International Journal of Pharmaceutics</i> , 2010, 390, 234-241.	5.2	123
152	Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 731-750.	8.5	169
153	Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. <i>Science Translational Medicine</i> , 2010, 2, 43ra56.	12.4	370
154	Pharmaceutical formulation affects titanocene transferrin interactions. <i>Dalton Transactions</i> , 2011, 40, 9580.	3.3	17
155	Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. <i>Nanomedicine</i> , 2011, 6, 55-68.	3.3	52
156	Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 417-423.	1.2	47
157	An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6728-6737.	0.9	181
158	Bilayer Matrix Composed of Polycation/DNA Complex and Sodium Alginate Gel as a Tumor Cell Catcher. <i>Macromolecular Bioscience</i> , 2011, 11, 1579-1585.	4.1	1
159	Aberrant Expression of TfR1/CD71 in Thyroid Carcinomas Identifies a Novel Potential Diagnostic Marker and Therapeutic Target. <i>Thyroid</i> , 2011, 21, 267-277.	4.5	41
160	Antibody-Based Immunotoxins for the Treatment of Cancer. <i>Antibodies</i> , 2012, 1, 39-69.	2.5	51
161	Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. <i>Cancer Letters</i> , 2012, 316, 151-156.	7.2	26
163	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012, 23, 1065-1074.	1.8	26
164	The core control system of intracellular iron homeostasis: A mathematical model. <i>Journal of Theoretical Biology</i> , 2012, 300, 91-99.	1.7	27

#	ARTICLE	IF	CITATIONS
165	Proteomic analysis of differentially expressed serum proteins in lung cancer. <i>Open Life Sciences</i> , 2012, 7, 343-353.	1.4	2
166	Repositioning of zoledronic acid for breast cancer using transferrin-conjugated liposome. <i>Journal of Pharmaceutical Investigation</i> , 2013, 43, 461-469.	5.3	9
167	Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 930-955.	5.4	34
168	Color Doppler Ultrasound and Gamma Imaging of Intratumorally Injected 500 nm Iron-Silica Nanoshells. <i>ACS Nano</i> , 2013, 7, 6367-6377.	14.6	45
169	Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1667-1675.	3.3	10
170	Role of Ca, Fe, Cu and Zn in breast cancer: study by X-ray fluorescence techniques and immunohistochemical analysis. <i>X-Ray Spectrometry</i> , 2013, 42, 303-311.	1.4	12
171	Premenopausal Plasma Ferritin Levels, HFE Polymorphisms, and Risk of Breast Cancer in the Nurses' Health Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 516-524.	2.5	11
172	Iron homeostasis in breast cancer. <i>Cancer Letters</i> , 2014, 347, 1-14.	7.2	89
173	Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy. <i>Journal of Membrane Biology</i> , 2014, 247, 291-307.	2.1	234
174	Iron homeostasis and anemia markers in early breast cancer. <i>Clinica Chimica Acta</i> , 2014, 434, 34-40.	1.1	42
175	Mammalian target of rapamycin coordinates iron metabolism with iron-sulfur cluster assembly enzyme and tristetraprolin. <i>Nutrition</i> , 2014, 30, 968-974.	2.4	28
176	Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1071-1076.	1.5	57
177	Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 326-348.	8.7	206
178	Tumor-Targeted and Clearable Human Protein-Based MRI Nanoprobe. <i>Nano Letters</i> , 2017, 17, 4096-4100.	9.1	61
179	Lipocalin-2 and iron trafficking in the tumor microenvironment. <i>Pharmacological Research</i> , 2017, 120, 146-156.	7.1	46
180	Convection-Enhanced Delivery. <i>Neurotherapeutics</i> , 2017, 14, 358-371.	4.4	204
181	Trace Elements and Healthcare: A Bioinformatics Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1005, 63-98.	1.6	19
182	A novel hydroxyphenyl hydrazone derivate YCLO426 inhibits cancer cell proliferation through sequestering iron. <i>Anti-Cancer Drugs</i> , 2017, 28, 1131-1140.	1.4	3

#	ARTICLE	IF	CITATIONS
183	Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool. <i>Tumor Biology</i> , 2017, 39, 101042831771765.	1.8	31
184	Expression of iron-related proteins in feline and canine mammary gland reveals unexpected accumulation of iron. <i>Biotechnic and Histochemistry</i> , 2017, 92, 584-594.	1.3	3
185	Isolation, Characterization and Bioactivities of an Extracellular Polysaccharide Produced from <i>Streptomyces</i> sp. MOE6. <i>Molecules</i> , 2017, 22, 1396.	3.8	27
186	Iron transport kinetics through blood-brain barrier endothelial cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 1168-1179.	2.4	41
187	Dysregulation of iron metabolism in cancer stem cells. <i>Free Radical Biology and Medicine</i> , 2019, 133, 216-220.	2.9	70
188	Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway. <i>Cancer Management and Research</i> , 2019, Volume 11, 6323-6341.	1.9	35
189	Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 296.	2.3	33
190	Transferrin Receptor-Mediated Sequential Intercellular Nanoparticles Relay for Tumor Deep Penetration and Sonodynamic Therapy. <i>Advanced Therapeutics</i> , 2019, 2, 1800152.	3.2	24
191	Iron as a Central Player and Promising Target in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 273.	4.1	199
192	An inductively coupled plasma-mass spectrometry (ICP-MS) linked immunoassay by means of iodinated antibodies for transferrin quantitative analysis in breast cancer cell lines. <i>Talanta</i> , 2019, 194, 336-342.	5.5	10
193	Identification SYT13 as a novel biomarker in lung adenocarcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 963-973.	2.6	15
194	Hepcidin and its therapeutic potential in neurodegenerative disorders. <i>Medicinal Research Reviews</i> , 2020, 40, 633-653.	10.5	43
195	Mitochondria regulation in ferroptosis. <i>European Journal of Cell Biology</i> , 2020, 99, 151058.	3.6	311
196	Targeting ferroptosis in breast cancer. <i>Biomarker Research</i> , 2020, 8, 58.	6.8	88
197	Iron and Cancer: 2020 Vision. <i>Cancer Research</i> , 2020, 80, 5435-5448.	0.9	91
198	Immunomodulatory Analogies Between Trophoblastic and Cancer Cells and Their Hosts. , 2001, , 190-208.		1
199	Immunotoxins: Selection of cell-surface antigens and their corresponding monoclonal antibodies. <i>Cancer Treatment and Research</i> , 1988, 37, 255-277.	0.5	4
200	Basic and Clinical Studies of Transferrin-Adriamycin Conjugates: Mechanisms for a New Approach to Drug Targeting. , 1988, , 173-180.		6

#	ARTICLE	IF	CITATIONS
201	A Systems Biology Approach to Iron Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2014, 844, 201-225.	1.6	96
202	Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1545-1563.	5.8	123
203	Targeting of Cytotoxic Drugs by Transferrin Receptors; Selective Killing of Acute Myelogenous Leukemia Cells. <i>Protides of the Biological Fluids; Proceedings of the Colloquium</i> , 1985, , 441-444.	0.1	11
204	Transferrin Receptors, HLA-A,B,C, and Amnion Antigens in Breast Adenocarcinoma. <i>Protides of the Biological Fluids; Proceedings of the Colloquium</i> , 1985, 32, 591-594.	0.1	3
205	IMMUNOBIOLOGY OF THE HUMAN TROPHOBLAST. , 1984, , 109-131.		14
206	Similarities between the transferrin receptor proteins on human reticulocytes and human placentae.. <i>Journal of Biological Chemistry</i> , 1981, 256, 12620-12623.	3.4	50
207	Biosynthesis of the human transferrin receptor in cultured cells.. <i>Journal of Biological Chemistry</i> , 1981, 256, 12888-12892.	3.4	306
208	Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA.. <i>Journal of Biological Chemistry</i> , 1992, 267, 9437-9442.	3.4	62
209	Physical characterization of the transferrin receptor in human placentae.. <i>Journal of Biological Chemistry</i> , 1981, 256, 9820-9823.	3.4	79
210	Current Concepts in Iron Metabolism. <i>Clinics in Haematology</i> , 1982, 11, 241-257.	2.3	31
211	Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. <i>Science Translational Medicine</i> , 2010, 2, 43ra56-43ra56.	12.4	232
212	Studies of the Transferrin Receptor on both Human Reticulocytes and Nucleated Human Cells in Culture. <i>Journal of Clinical Investigation</i> , 1982, 69, 853-865.	8.2	126
213	Heterogeneous distribution of transferrin receptors on parenchymal and nonparenchymal liver cells: biochemical and morphological evidence. <i>Blood</i> , 1987, 69, 264-270.	1.4	42
214	Hemochromatosis Enhances Tumor Progression via Upregulation of Intracellular Iron in Head and Neck Cancer. <i>PLoS ONE</i> , 2013, 8, e74075.	2.5	20
215	Cellular Iron Metabolism in Prognosis and Therapy of Breast Cancer. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 435-448.	0.4	66
216	Therapeutic Macromolecular Iron Chelators. <i>Current Medicinal Chemistry</i> , 2019, 26, 323-334.	2.4	6
217	Iron and Cell Proliferation. , 2001, , 39-69.		0
219	Cancer Therapeutic Applications of ENOX2 Proteins. , 2012, , 345-417.		1

#	ARTICLE	IF	CITATIONS
220	Oxidative Stress in Breast Cancer. , 2014, , 609-641.		0
221	Transferrin Receptors in Transformation and Differentiation. Protides of the Biological Fluids; Proceedings of the Colloquium, 1982, 29, 451-454.	0.1	2
222	Monoclonal Antibodies to Transferrin Receptors. , 1984, , 235-261.		2
223	Studies on the Iron Transport Mechanism of the Human Placenta. Juntendo J., Igaku, 1986, 32, 167-179.	0.1	0
224	The Transferrin Receptor. , 1987, , 297-320.		0
225	Receptor-mediated endocytosis of Transferrin-Neocarzinostatin conjugate. Drug Delivery System, 1987, 169-177.	0.0	0
226	Immunobiology of Human Breast Cancer. , 1987, , 167-224.		1
228	Iron Deficiency and Megaloblastic Anemias. Handbook of Experimental Pharmacology, 1992, , 137-222.	1.8	0
230	Current understandings and clinical translation of nanomedicines for breast cancer therapy. Advanced Drug Delivery Reviews, 2022, 180, 114034.	13.7	32
231	Selection of Cell Lines Resistant to Anti-Transferrin Receptor Antibody: Evidence for a Mutation in Transferrin Receptor. Molecular and Cellular Biology, 1984, 4, 1675-1681.	2.3	15
232	A Promising New Anti-Cancer Strategy: Iron Chelators Targeting CSCs. Acta Medica Okayama, 2020, 74, 1-6.	0.2	5
233	Transferrin receptor expression by stimulated cells in mixed lymphocyte culture. Immunology, 1985, 54, 559-64.	4.4	16
234	Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum. Clinical and Experimental Immunology, 1984, 57, 293-300.	2.6	63
235	Immunological studies of the human placenta: functional and morphological analysis of pregnancy-associated plasma protein A (PAPP-A). Immunology, 1981, 44, 577-83.	4.4	23
236	Transferrin receptor bearing cells in the peripheral blood of patients with rheumatoid arthritis. Clinical and Experimental Immunology, 1985, 62, 346-52.	2.6	19
237	Transferrin and transferrin receptor in human hypophysis and pituitary adenomas. American Journal of Pathology, 1998, 152, 413-22.	3.8	15
238	Effect of cerium lanthanide on Hela and MCF-7 cancer cell growth in the presence of transferring. Research in Pharmaceutical Sciences, 2010, 5, 119-25.	1.8	22
239	Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights, 2007, 2, 71-81.	1.4	13

#	ARTICLE	IF	CITATIONS
241	The Role of Iron in Cancer Progression. <i>Frontiers in Oncology</i> , 2021, 11, 778492.	2.8	55
242	Binding of the Anticancer Ti(IV) Complex Phenolati to Serum Proteins: Thermodynamic and Kinetic Aspects. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
243	Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer. <i>Oncogene</i> , 2022, 41, 2587-2596.	5.9	6
244	Binding of the anticancer Ti(IV) complex phenolaTi to serum proteins: Thermodynamic and kinetic aspects. <i>Journal of Inorganic Biochemistry</i> , 2022, 232, 111817.	3.5	4
245	Superstoichiometric Binding of the Anticancer Agent Titanocene Dichloride by Human Serum Transferrin and the Accompanying Lobe Closure. <i>Biochemistry</i> , 2022, 61, 795-803.	2.5	1
246	Human Trophoblast Antigens. <i>Immunology and Allergy Clinics of North America</i> , 1990, 10, 27-48.	1.9	4
247	Role of Fe, Transferrin and Transferrin Receptor in Anti-Tumor Effect of Vitamin C. <i>Cancers</i> , 2022, 14, 4507.	3.7	3
248	The role of the NDRG1 in the pathogenesis and treatment of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188871.	7.4	7
249	Prognostic Significance of Iron Metabolism Related Genes in Human Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 0, Volume 15, 203-216.	1.9	1
250	A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy. <i>Molecules</i> , 2023, 28, 3662.	3.8	1
251	A state-of-art of underlying molecular mechanisms and pharmacological interventions/nanotherapeutics for cisplatin resistance in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 166, 115337.	5.6	2
252	Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting. <i>PLoS ONE</i> , 2023, 18, e0293700.	2.5	0